Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on brain-targeted therapeutics, has announced significant progress in its Phase IIa feasibility trial of ONP-002 for mild traumatic brain injury (mTBI). The company has now dosed nine participants across three active clinical sites in Australia: Alfred Health, Mackay, and Royal Adelaide Hospital. This milestone comes as Oragenics also provides updates on its regulatory interactions with the U.S. Food and Drug Administration (FDA) and its compliance status with NYSE American.
The company had submitted a Type B meeting request briefing package to the FDA in July 2026, and has since received responses. Oragenics is currently reviewing these responses and remains committed to submitting an Investigational New Drug (IND) application by the end of 2026. This regulatory progress is crucial for advancing ONP-002, a potential first-in-class treatment for concussion and mTBI, toward U.S. clinical trials. The company plans to follow its Australian Phase IIa study with a U.S. Phase 2b trial, pending FDA approval.
In a separate development, Oragenics disclosed that it received a deficiency letter from NYSE American on August 26, 2026, concerning stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company has 45 days from receipt of the letter to submit a plan to regain compliance. Oragenics intends to submit such a plan within the required timeframe. If accepted, the plan would allow the company to maintain its listing during a cure period, subject to periodic review, with a compliance deadline of February 25, 2028.
These updates underscore the dual challenges and opportunities facing Oragenics as it navigates the complex landscape of clinical development and public market regulations. The advancement of the ONP-002 trial is a positive signal for the company's pipeline, which leverages its proprietary intranasal delivery platform. This platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders, according to the company's announcements. The successful development of ONP-002 could address significant unmet medical needs in neurological care, offering a new therapeutic option for patients suffering from concussions and mTBI.
However, the NYSE American deficiency letter highlights the company's financial position, which is typical for clinical-stage biotech firms that incur substantial R&D costs without generating revenue. The company's ability to regain compliance will depend on its financial strategies and potential capital raises. Investors will be watching closely to see how Oragenics addresses these issues while advancing its clinical programs.
For more information on Oragenics and its developments, visit the company's newsroom at https://nnw.fm/OGEN.
